Article info
PDFExtended reports
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
- Correspondence to:
Dr Michael H Schiff
Clinical Research, Denver Arthritis Clinic, 200 Spruce Street, Suite 100, Denver, CO 80230, USA; crendon{at}denverarthritisclinic.com
Citation
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
Publication history
- Accepted January 2, 2006
- First published January 26, 2006.
Online issue publication
April 11, 2023
Article Versions
- Previous version (9 January 2022).
- Previous version (9 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Copyright 2006 by Annals of the Rheumatic Diseases